Frequently Asked Questions
Does Medicare cover cognitive screening?
Yes — Medicare Part B covers cognitive impairment detection as part of the Annual Wellness Visit at $0 cost. Your doctor performs a brief cognitive assessment to establish a baseline and identify any concerning changes. If concerns are found, Medicare also covers a comprehensive cognitive assessment by a specialist at 80% Part B coinsurance. If you have not had a cognitive screening at your Annual Wellness Visit, ask your doctor to include it.
What cognitive tests does Medicare use?
Common brief cognitive screening tools used in primary care include: Mini-Cog (3-minute test: recall 3 words plus draw a clock face), MoCA (Montreal Cognitive Assessment — 10-15 minutes, tests multiple cognitive domains), MMSE (Mini Mental State Examination — 10 minutes, widely used), and GPCOG (GP Assessment of Cognition). These are not diagnostic — they identify the need for further evaluation. A score below threshold triggers referral for comprehensive neuropsychological testing.
What is the difference between normal aging and mild cognitive impairment?
Normal aging: occasional forgetting of names or words, slower processing speed, needing more time to learn new things — but not affecting daily function. Mild Cognitive Impairment (MCI): memory or thinking changes that are noticeable to the person or family members, measurable on testing, but not yet significantly impairing daily activities. Dementia: memory and cognitive changes significant enough to impair daily function and independence. MCI does not inevitably progress to dementia — approximately 30-40% revert to normal cognition.
What should I do if a cognitive screening shows a problem?
A below-threshold score on a brief screening triggers further evaluation — not a diagnosis. Next steps: comprehensive neuropsychological testing by a neuropsychologist (Medicare-covered), brain imaging (MRI, PET scan), blood work to rule out treatable causes (thyroid, B12 deficiency, medication effects), and review of all medications for cognitive side effects. Many treatable conditions mimic dementia: depression, medication interactions, vitamin deficiencies, sleep apnea, and thyroid problems.
Are there FDA-approved treatments for early Alzheimer's?
Yes — lecanemab (Leqembi) and donanemab (Kisunla) are FDA-approved monoclonal antibodies for early Alzheimer's disease (mild cognitive impairment and mild dementia due to Alzheimer's). They reduce amyloid buildup in the brain and slow cognitive decline in early stages. They require amyloid confirmation (PET scan or CSF test) and are administered by infusion. Medicare covers these medications as outpatient infusions, though coverage pathways continue to evolve.
The window for meaningful intervention in cognitive decline is early — when changes are subtle enough that many people dismiss them as normal aging. Medicare covers screening, and new treatments for early Alzheimer's disease make early detection more clinically meaningful than ever. Here is what cognitive screening involves and what to do with the results.
Why Early Screening Matters Now More Than Ever
Until recently, early detection of cognitive decline had limited direct treatment implications — there were no disease-modifying therapies. That changed with the FDA approval of lecanemab (Leqembi) and donanemab (Kisunla) for early Alzheimer's — the first drugs to slow cognitive decline rather than just manage symptoms. These treatments are only effective and appropriate in the early stages (mild cognitive impairment to mild dementia). By the time dementia is obvious, the treatment window has closed. Early screening now has direct treatment implications.
Cognitive Screening at the Annual Wellness Visit
Your Medicare Annual Wellness Visit includes a structured cognitive assessment. In practice, many primary care doctors perform this informally or skip it. To ensure it's done properly: tell your doctor you specifically want a cognitive screening. Request the MoCA (Montreal Cognitive Assessment) — it is the most sensitive brief screen for mild cognitive impairment and takes 10–15 minutes.
The MoCA tests: short-term memory recall, visuospatial abilities (draw a clock), executive function, attention, language, and orientation. A score of 26/30 or higher is generally considered normal. 18–25 suggests mild cognitive impairment. Below 17 suggests moderate impairment — though scores must always be interpreted in the context of education level, language, and other factors.
Red Flags That Warrant Immediate Evaluation
Don't wait for your next Annual Wellness Visit if you notice:
- Getting lost in familiar places
- Difficulty managing finances or paying bills accurately
- Repeating the same questions or stories within the same conversation
- Inability to follow a TV show or conversation that previously was easy
- Missing medications or being uncertain whether medications were taken
- Family members expressing concern about memory changes
Rule Out Reversible Causes First
Before accepting a diagnosis of primary cognitive decline, ensure these reversible causes have been excluded:
- Medications: Anticholinergics (diphenhydramine/Benadryl, overactive bladder drugs), benzodiazepines, certain antidepressants, and blood pressure medications can cause significant cognitive impairment that reverses when the medication is stopped or changed
- Vitamin B12 deficiency: Common in seniors (especially on metformin), causes reversible cognitive decline — test with a serum B12 level
- Thyroid disease: Both hypothyroidism and hyperthyroidism impair cognition — TSH screening rules this out
- Sleep apnea: Untreated sleep apnea causes cognitive impairment that improves significantly with CPAP treatment
- Depression: "Pseudodementia" — depression in seniors presents with cognitive symptoms that resolve with depression treatment
- Vitamin D deficiency: Associated with cognitive decline and worth correcting regardless
If Cognitive Decline Is Confirmed
A confirmed MCI or early dementia diagnosis triggers several Medicare-covered interventions: referral to a neurologist or geriatric psychiatrist, comprehensive neuropsychological testing, brain MRI, Medicare-covered medications (cholinesterase inhibitors like donepezil for symptom management), and advance care planning conversation covered under Medicare. Asking your doctor about clinical trial eligibility at major academic medical centers is also worthwhile — new research is actively enrolling.
- Request a MoCA cognitive screening at your Annual Wellness Visit — ask by name
- If concerned between visits, schedule a separate cognitive assessment — don't wait
- Rule out reversible causes first: medications, B12, thyroid, sleep apnea, depression
- Early detection is more actionable than ever — new FDA-approved treatments exist for early stages
- Hearing loss is the #1 modifiable risk factor — treat it now, regardless of cognitive screening results